SG11201906681PA - N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors for treating cancer - Google Patents
N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors for treating cancerInfo
- Publication number
- SG11201906681PA SG11201906681PA SG11201906681PA SG11201906681PA SG11201906681PA SG 11201906681P A SG11201906681P A SG 11201906681PA SG 11201906681P A SG11201906681P A SG 11201906681PA SG 11201906681P A SG11201906681P A SG 11201906681PA SG 11201906681P A SG11201906681P A SG 11201906681PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- cyclopropylmethyl
- pyrazol
- pyridin
- cyclohexane
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- XREIADPMSAUOHY-UHFFFAOYSA-N 4-N-[4-[5-(cyclopropylmethyl)-1-methylpyrazol-4-yl]pyridin-2-yl]cyclohexane-1,4-diamine Chemical class C1(CC1)CC1=C(C=NN1C)C1=CC(=NC=C1)NC1CCC(CC1)N XREIADPMSAUOHY-UHFFFAOYSA-N 0.000 title abstract 2
- 102000008122 Casein Kinase I Human genes 0.000 abstract 3
- 108010049812 Casein Kinase I Proteins 0.000 abstract 3
- 102000006940 Interleukin-1 Receptor-Associated Kinases Human genes 0.000 abstract 3
- 108010072621 Interleukin-1 Receptor-Associated Kinases Proteins 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 241000234282 Allium Species 0.000 abstract 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 abstract 1
- FNFMQIWXTYFRKA-UHFFFAOYSA-N cyclohexane-1,4-diamine Chemical class NC1[CH]CC(N)CC1 FNFMQIWXTYFRKA-UHFFFAOYSA-N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 150000003217 pyrazoles Chemical class 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
International Patent Classification: CO7D 401/04 (2006.01) A61K 31/506 (2006.01) CO7D 403/04 (2006.01) A61K 31/4155 (2006.01) C07D 417/04 (2006.01) A61K 31/427 (2006.01) A61K 31/4439 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 09 August 2018 (09.08.2018) WIPO I PCT omit °nolo milli offi onion° oimIE (10) International Publication Number WO 2018/142393 Al PCT/IL2018/050100 (22) International Filing Date: 30 January 2018 (30.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/453,192 01 February 2017 (01.02.2017) US (71) Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW [IL/IL]; Hi Tech Park, Edmond J. Safra Campus, Givat Ram, 9139002 Jerusalem (IL). (72) Inventors: LI, Dansu; 2690 Fawn Lane, Warrington, Pennsylvania 18976 (US). SNIR-ALKALAY, Irit; 63/3 Habosem St., 9076901 Mevasseret Zion (IL). VACCA, Joseph; 733 Indian Creek Road, Telford, Pennsylvania 18969 (US). BEN-NERIAH, Yinon; 5 Mevo Duvdevan St., POB 1691, 9071923 Mevasseret Zion (IL). VENKAT- AC-IALAM, Avanthika; Jerusalem (IL). (74) Agent: VOLMAN, Gail; Dr. Shlomo Cohen & Co., B. S. R Tower 3, 5 Kineret St., 5126237 Bnei Brak (IL). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: N1 -(4-(5-(CYCLOPROPYLMETHYL)-1 -METHYL-1 H-PYRAZOL-4-YL)PYRIDIN-2-YL)CYCLOHEXANE-1,4- DIAMINE DERIVATIVES AND RELATED COMPOUNDS AS CK1 AND/OR IRAKI INHIBITORS FOR TREATING CANCER W O 20 18/ 142393 Al R2 (57) : The present invention provides pyra- zole derivatives of Formula (I), and in par- ticular N1 -(4-(5-(cyclopropylmethyl)-1 -methy1-1H-pyrazol-4-y1) pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related com- pounds as casein kinase 1 (CK1) and/or interleukin 1 receptor asso- ciated kinase 1 (IRAKI) inhibitors for treating cancer, inflammatory and immune related disorders. (I)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762453192P | 2017-02-01 | 2017-02-01 | |
| PCT/IL2018/050100 WO2018142393A1 (en) | 2017-02-01 | 2018-01-30 | N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906681PA true SG11201906681PA (en) | 2019-08-27 |
Family
ID=61198874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906681PA SG11201906681PA (en) | 2017-02-01 | 2018-01-30 | N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors for treating cancer |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11072599B2 (en) |
| EP (1) | EP3577108B1 (en) |
| JP (1) | JP7142646B2 (en) |
| KR (1) | KR20190115017A (en) |
| CN (1) | CN110475771B (en) |
| AU (1) | AU2018215809B2 (en) |
| CA (1) | CA3052247A1 (en) |
| ES (1) | ES2902885T3 (en) |
| IL (1) | IL268128B2 (en) |
| MX (1) | MX2019009083A (en) |
| NZ (1) | NZ755447A (en) |
| RU (1) | RU2761457C2 (en) |
| SG (1) | SG11201906681PA (en) |
| TW (1) | TW201837027A (en) |
| WO (1) | WO2018142393A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3090063A1 (en) * | 2018-02-08 | 2019-08-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use |
| WO2021000957A1 (en) * | 2019-07-04 | 2021-01-07 | 北京国鸿生物医药科技有限公司 | Heterocyclic compound and pharmaceutical composition thereof and use thereof |
| US20230339900A1 (en) * | 2020-09-17 | 2023-10-26 | Janssen Pharmaceutica Nv | Casein kinase 1 delta modulators |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007129195A2 (en) * | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
| CA2802641C (en) | 2010-07-13 | 2019-03-12 | Nidhi Arora | Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators |
| CN104906103B (en) | 2010-12-14 | 2018-05-18 | 电泳有限公司 | Casein kinase 1 δ (CK1 δ) inhibitor |
| KR101990605B1 (en) | 2011-11-04 | 2019-06-18 | 자스코 파머수티컬스, 엘엘씨 | Aminopyrimidine kinase inhibitors |
| JP2016531870A (en) | 2013-09-27 | 2016-10-13 | ニンバス アイリス， インコーポレイテッド | IRAK inhibitors and uses thereof |
| EP3057956B1 (en) | 2013-10-18 | 2021-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
| NZ730728A (en) * | 2014-11-20 | 2022-04-29 | Merck Patent Gmbh | Heteroaryl compounds as irak inhibitors and uses thereof |
| EP3273955A4 (en) | 2015-03-23 | 2019-05-01 | The University of Melbourne | Treatment of respiratory diseases |
| US10376511B2 (en) * | 2015-08-04 | 2019-08-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Pyrazole pyrimidine derivative and uses thereof |
-
2018
- 2018-01-30 SG SG11201906681PA patent/SG11201906681PA/en unknown
- 2018-01-30 KR KR1020197025024A patent/KR20190115017A/en not_active Application Discontinuation
- 2018-01-30 WO PCT/IL2018/050100 patent/WO2018142393A1/en unknown
- 2018-01-30 EP EP18705024.0A patent/EP3577108B1/en active Active
- 2018-01-30 JP JP2019561389A patent/JP7142646B2/en active Active
- 2018-01-30 AU AU2018215809A patent/AU2018215809B2/en active Active
- 2018-01-30 ES ES18705024T patent/ES2902885T3/en active Active
- 2018-01-30 RU RU2019127038A patent/RU2761457C2/en active
- 2018-01-30 CA CA3052247A patent/CA3052247A1/en active Pending
- 2018-01-30 MX MX2019009083A patent/MX2019009083A/en unknown
- 2018-01-30 US US16/482,199 patent/US11072599B2/en active Active
- 2018-01-30 CN CN201880022829.8A patent/CN110475771B/en active Active
- 2018-01-30 IL IL268128A patent/IL268128B2/en unknown
- 2018-01-30 NZ NZ755447A patent/NZ755447A/en unknown
- 2018-01-30 TW TW107103255A patent/TW201837027A/en unknown
-
2021
- 2021-07-26 US US17/384,922 patent/US20220017493A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL268128B (en) | 2022-11-01 |
| US11072599B2 (en) | 2021-07-27 |
| AU2018215809A1 (en) | 2019-08-15 |
| NZ755447A (en) | 2023-05-26 |
| AU2018215809B2 (en) | 2021-12-23 |
| JP7142646B2 (en) | 2022-09-27 |
| WO2018142393A1 (en) | 2018-08-09 |
| US20200354340A1 (en) | 2020-11-12 |
| EP3577108B1 (en) | 2021-10-20 |
| EP3577108A1 (en) | 2019-12-11 |
| MX2019009083A (en) | 2019-09-10 |
| ES2902885T8 (en) | 2022-04-06 |
| US20220017493A1 (en) | 2022-01-20 |
| JP2020505468A (en) | 2020-02-20 |
| IL268128B2 (en) | 2023-03-01 |
| CA3052247A1 (en) | 2018-08-09 |
| RU2019127038A (en) | 2021-03-02 |
| ES2902885T3 (en) | 2022-03-30 |
| IL268128A (en) | 2019-09-26 |
| CN110475771A (en) | 2019-11-19 |
| RU2019127038A3 (en) | 2021-03-17 |
| CN110475771B (en) | 2022-09-02 |
| RU2761457C2 (en) | 2021-12-08 |
| TW201837027A (en) | 2018-10-16 |
| KR20190115017A (en) | 2019-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201900501RA (en) | Cannabis composition | |
| SG11201909303TA (en) | Point of delivery cold slurry generation | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201805368YA (en) | Anthelmintic depsipeptide compounds | |
| SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201807596YA (en) | Gitr antibodies, methods, and uses | |
| SG11201807549TA (en) | Combination of a cxcr4 antagonist and an immune checkpoint inhibitor | |
| SG11201909837YA (en) | Methods for treating lung disorders | |
| SG11201900361RA (en) | Methods of treating prostate cancer | |
| SG11201901228QA (en) | Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide | |
| SG11201902567WA (en) | Expec glycoconjugate vaccine formulations | |
| SG11201906681PA (en) | N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors for treating cancer | |
| SG11201811804QA (en) | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors | |
| SG11201810801QA (en) | Brain delivery protein | |
| SG11201909840TA (en) | Treatment of epithelial cysts by intracystic injection of antineoplastic particles |